EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Serum Protein Panel Facilitates Surgical Decision-Making for Barcelona Stage B Hepatocellular Carcinoma

Jin-Hua Wang, Liang-Liang Ren, Wan-Jun Zhang, Xiao-Hua Xing, Jun-Qing Li, Chao-Ying Li, Wei-Jie Qin, Xiao-Long Liu, Ying Jiang

Molecular & Cellular Proteomics · 2026-11 · 25 (11) · 101674

DOI: 10.1016/j.mcpro.2026.101674 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular & Cellular Proteomics, 2026-11. Verfasst von Jin-Hua Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Medical Proteomics, National Center for Protein Sciences (Beijing), Beijing, China. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Natural Science Foundation of Beijing Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To address the clinical heterogeneity that limits uniform treatment recommendations, we developed a serum proteomic-based prognostic model for predicting surgical outcomes in patients with Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC). Preoperative serum samples from patients with HCC undergoing curative resection were retrospectively collected and profiled using nanoparticle-enhanced data-independent acquisition mass spectrometry. A prognostic risk model was developed in a training cohort (N = 52, BCLC stage B) using 5-fold cross-validated Lasso-Cox machine learning, with overall survival as the primary endpoint. The model was validated in an independent BCLC stage B cohort (N = 22), extended to a single huge HCC cohort (N = 26, BCLC stage A with a solitary tumor ≥10 cm), and benchmarked against a comparison cohort (N = 190, BCLC stage 0/A without huge HCC). Orthogonal validation was performed by parallel reaction monitoring in an exploration cohort (N = 51, BCLC stage B). Among 2381 identified proteins, a three-protein panel (LCP1, DOK3, and CNN2) was selected. The model showed strong predictive accuracy for 3-year overall survival in the training cohort (area under the curve [AUC] = 0.936, sensitivity = 0.988, specificity = 0.834), outperforming the clinical Kinki criteria. It also performed well in the validation cohort (AUC = 0.812, sensitivity = 0.875, specificity = 0.786) and the extended cohort of huge HCC patients (AUC = 0.758, sensitivity = 0.709, specificity = 0.852). Notably, low-risk BCLC stage B patients showed prognosis comparable to the comparison cohort, suggesting potential surgical benefit. Parallel reaction monitoring validation confirmed the model's prognostic value (AUC = 0.800, sensitivity = 0.870, specificity = 0.700). This serum proteomic-based model accurately predicts surgical outcomes for BCLC stage B HCC and outperforms clinical stratification. By identifying low-risk patients who may benefit from surgery, it facilitates personalized treatment planning and may improve survival and quality of life.

Schlagwörter

Stichwörter der Autor:innen

Barcelona Clinic liver cancer Bmachine learningprognosisserum proteomesurgery decision

Autor:innen und Institutionen

  • State Key Laboratory of Medical Proteomics, National Center for Protein Sciences (Beijing), Beijing, China.
  • Department of Pathology, Institute of Oncology, School of Basic Medical Science, Fujian Medical University, Fuzhou, China.
  • State Key Laboratory of Medical Proteomics, National Center for Protein Sciences (Beijing), Beijing, China; School of Basic Medical Science, Anhui Medical University, Hefei, China.
  • State Key Laboratory of Medical Proteomics, National Center for Protein Sciences (Beijing), Beijing, China; Beijing Proteome Research Center, Beijing, China.
  • State Key Laboratory of Medical Proteomics, National Center for Protein Sciences (Beijing), Beijing, China; Beijing Proteome Research Center, Beijing, China. Electronic address: aunp_dna@126.com.
  • Department of Pathology, Institute of Oncology, School of Basic Medical Science, Fujian Medical University, Fuzhou, China. Electronic address: xiaoloong.liu@gmail.com.

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Natural Science Foundation of Beijing Municipality

Zitieren

APA

Wang, J. H., Ren, L. L., Zhang, W. J., Xing, X. H., Li, J. Q., Li, C. Y., Qin, W. J., Liu, X. L., & Jiang, Y. (2026). Serum Protein Panel Facilitates Surgical Decision-Making for Barcelona Stage B Hepatocellular Carcinoma. Molecular & Cellular Proteomics, 25(11), 101674. https://doi.org/10.1016/j.mcpro.2026.101674

Vancouver

Wang JH, Ren LL, Zhang WJ, Xing XH, Li JQ, Li CY, et al. Serum Protein Panel Facilitates Surgical Decision-Making for Barcelona Stage B Hepatocellular Carcinoma. Molecular & Cellular Proteomics. 2026;25(11):101674. doi:10.1016/j.mcpro.2026.101674

BibTeX
@article{Wang2026,
  author = {Wang, Jin-Hua and Ren, Liang-Liang and Zhang, Wan-Jun and Xing, Xiao-Hua and Li, Jun-Qing and Li, Chao-Ying and Qin, Wei-Jie and Liu, Xiao-Long and Jiang, Ying},
  title = {Serum Protein Panel Facilitates Surgical Decision-Making for Barcelona Stage B Hepatocellular Carcinoma},
  journal = {Molecular & Cellular Proteomics},
  year = {2026},
  volume = {25},
  number = {11},
  pages = {101674},
  doi = {10.1016/j.mcpro.2026.101674}
}
Kostenlos starten →